We are live on ! Find out more
FC

Finepoint Capital Portfolio holdings

AUM $1.95B
1-Year Est. Return 45.61%
This Fund
S&P 500
This Quarter Est. Return
-12.45%
1 Year Est. Return
+45.61%
3 Year Est. Return
+24.83%
5 Year Est. Return
+26.66%
10 Year Est. Return
–
AUM
$201M
AUM Growth
-$88.3M
Cap. Flow
-$46.1M
Cap. Flow %
-22.95%
Top 10 Hldgs %
75.88%
Holding
39
New
2
Increased
12
Reduced
2
Closed
9

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$12.7M
2
ARVN icon
Arvinas
ARVN
+$2.29M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$2.25M
4
ASND icon
Ascendis Pharma A/S
ASND
+$2.25M
5
FOLD
Amicus Therapeutics
FOLD
+$2.11M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$22M
2
SAGE
Sage Therapeutics
SAGE
+$16.8M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$14.4M
4
CLVT icon
Clarivate
CLVT
+$11.9M
5
BHC icon
Bausch Health
BHC
+$9.32M

Sector Composition

Rank Sector Weight
1 Healthcare 99.35%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
1
MoonLake Immunotherapeutics
MLTX
$1.64B
$18.9M 9.41%
331,416
+29,416
+10% +$1.62M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$18.1M 9.02%
1,489,025
+163,250
+12% +$2.11M
SRPT icon
3
Sarepta Therapeutics
SRPT
$1.82B
$17.6M 8.78%
145,357
+19,900
+16% +$2.25M
PRTA icon
4
Prothena Corp
PRTA
$453M
$16.9M 8.39%
349,300
+32,000
+10% +$1.9M
LKFT
5
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$15.8M 7.89%
458,659
+51,800
+13% +$2.02M
ASND icon
6
Ascendis Pharma A/S
ASND
$17.1B
$15.3M 7.64%
163,772
+24,000
+17% +$2.25M
SWTX
7
DELISTED
SpringWorks Therapeutics
SWTX
$12.9M 6.41%
556,928
-51,700
-8% -$1.41M
CYTK icon
8
Cytokinetics
CYTK
$10.9B
$12.7M 6.33%
431,693
+62,600
+17% +$2.08M
CERE
9
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$12.3M 6.12%
563,345
+70,800
+14% +$1.77M
RVMD icon
10
Revolution Medicines
RVMD
$39.6B
$11.8M 5.89%
+427,000
New +$12.7M
ACAD icon
11
Acadia Pharmaceuticals
ACAD
$4.38B
$11.6M 5.78%
556,553
-290,400
-34% -$7.89M
ARVN icon
12
Arvinas
ARVN
$517M
$9.91M 4.94%
504,700
+93,200
+23% +$2.29M
TVTX icon
13
Travere Therapeutics
TVTX
$5.27B
$8.01M 3.99%
895,821
+134,100
+18% +$1.89M
MORF
14
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$7.45M 3.71%
325,356
+37,800
+13% +$1.98M
RLAY icon
15
Relay Therapeutics
RLAY
$4.34B
$7.32M 3.65%
870,870
+169,300
+24% +$1.82M
SLDB icon
16
Solid Biosciences
SLDB
$858M
$2.42M 1.21%
961,251
– –
CLDI icon
17
Calidi Biotherapeutics
CLDI
$2.3M
$416K 0.21%
+1,042
New +$1.05M
AAC.WS
18
DELISTED
Ares Acquisition Corporation Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
AAC.WS
$334K 0.17%
504,706
– –
BTWNW
19
DELISTED
Bridgetown Holdings Limited Warrants
BTWNW
$304K 0.15%
895,000
– –
CVIIW
20
DELISTED
Churchill Capital Corp VII Warrants
CVIIW
$169K 0.08%
548,000
– –
CLDI.WS
21
DELISTED
Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
$144K 0.07%
655,200
– –
CDAQW
22
DELISTED
Compass Digital Acquisition Corp. Warrant
CDAQW
$101K 0.05%
459,906
– –
CCVI.WS
23
DELISTED
Churchill Capital Corp VI Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share
CCVI.WS
$86.4K 0.04%
540,000
– –
ROSS.WS
24
DELISTED
Ross Acquisition Corp II Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
ROSS.WS
$49K 0.02%
439,666
– –
CNDA.WS
25
DELISTED
Concord Acquisition Corp II Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50
CNDA.WS
$42.6K 0.02%
408,333
– –
1
2

Similar funds

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return

Finepoint Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Finepoint Capital held 39 positions worth $201M, down 31% from $289M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Finepoint Capital withdrew a net $46.1M in Q3 2023, closing 9 positions and reducing 2 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $22M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier, followed by Technology.

Against the trend, Finepoint Capital opened a new position in Revolution Medicines worth $11.8M.

  • Finepoint Capital's largest Q3 2023 buy was Revolution Medicines: 427,000 shares worth $11.8M.
  • Finepoint Capital added most to Arvinas in Q3 2023, an estimated $2.29M increase.
  • Finepoint Capital's biggest Q3 2023 reduction was Acadia Pharmaceuticals, cutting an estimated $7.89M.
  • Finepoint Capital fully exited Apellis Pharmaceuticals in Q3 2023, selling an estimated $22M.
  • Finepoint Capital's ten largest holdings make up 76% of its $201M portfolio in Q3 2023.
  • Finepoint Capital opened 2 new positions and closed 9 in Q3 2023.
  • Finepoint Capital's portfolio value fell 31% quarter-over-quarter to $201M.

Based on Finepoint Capital's 13F filing for Q3 2023, filed 13 Nov 2023.